Why insider trading matters?

Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.

- Prof. B. Espen Eckbo, Dartmouth College
AIM ImmunoTech Inc. (AIM)
Sector: Healthcare; Industry: Biotechnology

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-07-16 EQUELS THOMAS K. CEO & President Buy 15,625 $1.92 $30,000 No
2021-02-25 APPELROUTH STEWART Director Buy 10,638 $2.35 $24,999 No
2021-02-24 EQUELS THOMAS K. CEO & President Buy 11,062 $2.26 $25,000 No
2020-12-17 EQUELS THOMAS K. CEO Buy 14,535 $1.72 $25,000 No
2020-09-03 EQUELS THOMAS K. CEO & President Buy 12,316 $2.03 $25,001 No
2020-08-21 EQUELS THOMAS K. CEO Buy 10,730 $2.33 $25,001 No
2019-06-27 EQUELS THOMAS K. Exec. Vice Chairman/CEO/Pres. Buy 2,632 $4.37 $11,502 No
2019-06-21 EQUELS THOMAS K. Exec. Vice Chairman/CEO/Pres. Buy 29,404 $4.03 $118,498 No
2019-06-21 STRAYER DAVID R Chief Science/Medical Officer Buy 2,481 $4.03 $9,998 No
2019-06-21 RODINO III PETER W. Dir Govt Relations/Sectry Buy 8,695 $4.03 $35,041 No
2019-06-21 APPELROUTH STEWART Director Buy 9,677 $4.03 $38,998 No
2019-06-21 SPRINGATE WAYNE S Sr. VP of Operations Buy 5,211 $4.03 $21,000 No
2019-06-21 MITCHELL WILLIAM M Director Buy 9,677 $4.03 $38,998 No
2019-06-21 EQUELS THOMAS K. Exec. Vice Chairman/CEO/Pres. Buy 29,404 $4.03 $118,498 No
2019-03-19 EQUELS THOMAS K. Exec. Vice Chairman/CEO/Pres. Buy 13,400 $0.18 $2,352 No
2018-11-30 EQUELS THOMAS K. Exec. Vice Chairman/CEO/Pres. Buy 20,000 $0.19 $3,845 No
2018-11-05 APPELROUTH STEWART Director Buy 25,238 $0.22 $5,552 No
2018-10-26 EQUELS THOMAS K. Exec. Vice Chairman/CEO/Pres. Buy 3,500 $0.20 $710 No
2018-10-25 EQUELS THOMAS K. Exec. Vice Chairman/CEO/Pres. Buy 100,000 $0.20 $20,000 No
2018-07-27 EQUELS THOMAS K. Exec. Vice Chairman/CEO/Pres. Buy 34,483 $0.29 $10,000 No
2018-07-24 APPELROUTH STEWART Director Buy 126,000 $0.31 $39,060 No
2018-07-23 EQUELS THOMAS K. Exec. Vice Chairman/CEO/Pres. Buy 112,904 $0.31 $35,000 No
2018-07-23 SPRINGATE WAYNE S Sr. VP of Operations Buy 32,259 $0.31 $10,000 No
2018-07-23 PASCALE ADAM CFO Buy 32,259 $0.31 $10,000 No
2018-04-27 APPELROUTH STEWART Director Buy 100,000 $0.32 $32,000 No
2018-04-27 EQUELS THOMAS K. CEO, President Buy 32,000 $0.32 $10,240 No
2017-05-02 Rodino Peter W. III Exec Dir Govt Relations/Secrty Buy 15,873 $0.63 $10,000 No
2017-05-02 Springate Wayne S. Sr VP of Operations Buy 15,873 $0.63 $10,000 No
2017-05-02 STRAYER DAVID R Chief Science/Medical Officer Buy 7,937 $0.63 $5,000 No
2017-05-02 Pascale Adam CFO Buy 15,873 $0.63 $10,000 No

Insider Smart

Mohawk Group Holdings, Inc. (MWK) - Multiple insiders bought MWK in June around $5, stock moved sideways for a month then made a 60% jump in 10 days. Patience is the key.